Skip to main content
. Author manuscript; available in PMC: 2012 Dec 10.
Published in final edited form as: Nat Rev Clin Oncol. 2012 Feb 28;9(4):223–229. doi: 10.1038/nrclinonc.2012.21

Table 2.

Multivariable analysis of post-neoadjuvant tumor factors in P024 trial22

Post-therapy factors RFS Breast cancer-specific
survival


HR (95% CI) P HR (95% CI) P
Tumor stage (T1 or 2 vs T3 or 4) 2.8 (1.4–5.4) 0.003 4.4 (1.7–11.2) 0.002

Node status (+ versus −) 3.2 (1.5–6.9) 0.004 3.9 (1.1–13.7) 0.04

Ki-67 levels per 2.7-fold increase 1.3 (1.1–1.6) 0.003 1.4 (1.07–1.9) 0.01

ER, Allred score (0–2 versus 3–8) 2.8 (1.2–6.4) 0.02 7.0 (2.4–20.9) <0.001

Abbreviations: ER, estrogen receptor; HR, hazard ratio; RFS, recurrence-free survival. Permission obtained from National Cancer Institute © Ellis, M. J. et al. J. Natl Cancer Inst. 100, 1380–1388 (2008).22